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ABSTRACT
Introduction Obstructive sleep apnoea (OSA) and type 
2 diabetes mellitus (T2DM) often occur concurrently, 
and untreated OSA may potentially amplify the high 
risk of cardiovascular disease in T2DM. Compliance 
with continuous positive airway pressure (CPAP), the 
conventional treatment for OSA, can be poor and 
considering weight loss is the most effective treatment 
for OSA. This trial examines whether the glucagon- like 
peptide-1 receptor agonist liraglutide, a glucose- lowering 
therapy associated with significant weight loss used in 
T2DM, can improve the severity and symptoms of OSA.
Methods and analysis This is an outpatient, single- 
centred, open- labelled, prospective, phase IV randomised 
controlled trial in a two- by- two factorial design. One 
hundred and thirty- two patients with newly diagnosed 
OSA (apnoea–hypopnoea index (AHI) ≥15 events/hour), 
and existing obesity and T2DM (glycated haemoglobin 
(HbA1c) ≥47 mmol/mol), will be recruited from diabetes 
and sleep medicine outpatient clinics in primary and 
secondary care settings across Liverpool. Patients will 
be allocated equally, using computer- generated random, 
permuted blocks of unequal sizes, to each of the four 
treatment arms for 26 weeks: (i) liraglutide (1.8 mg 
once per day) alone, (ii) liraglutide 1.8 mg once per day 
with CPAP, (iii) CPAP alone (conventional care) or (iv) no 
treatment (control). The primary outcome measure is 
change in OSA severity, determined by AHI. Secondary 
outcome measures include effects on glycaemic control 
(glycated haemoglobin (HbA1c)), body weight and quality 
of life measures. Exploratory measures include measures 
of physical activity, MRI- derived measures of regional body 
Strengths and limitations of this study
 ► This is the first study to address the treatment of 
type 2 diabetes mellitus and obstructive sleep ap-
noea concomitantly using an glucagon- like pep-
tide-1 receptor agonist (GLP- 1RA) (liraglutide) in 
combination with continuous positive airway pres-
sure to target long- term weight loss and immediate 
symptomatic relief.
 ► This study is designed to examine the impact of 
weight- loss- induced reductions in apnoea–hypop-
noea index (AHI).
 ► Further assessment of changes in glycaemic control 
and body composition provides metabolic, mechan-
ical and physiological correlates.
 ► The sample size is relatively small, though it pro-
vides sufficient statistical power to address the pri-
mary research question.
 ► Higher doses of liraglutide 3.0 mg once per day and 
newer GLP- 1RAs (semaglutide) would produce a 
greater magnitude of weight loss (and thus poten-
tially a greater reduction in AHI); although recently 
licenced these were not available at study initiation, 
nor are widely available currently.
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composition including fat mass (abdominal subcutaneous, visceral, neck 
and liver fat) and skeletal muscle mass (cross- sectional analysis of thigh), 
indices of cardiac function (using transthoracic echocardiography) and 
endothelial function.
Ethical approval The study has been approved by the North West 
Liverpool Central Research Ethics Committee (14/NW/1019) and it is 
being conducted in accordance with the Declaration of Helsinki and Good 
Clinical Practice.
Trial registration numbers ISRCTN16250774. EUDRACT No. 2014-
000988-41. UTN U1111-1139-0677.
INTRODUCTION
Obstructive sleep apnoea (OSA) is characterised by 
repeated closure of the upper airway during sleep and 
it has been associated with significant cardiovascular 
morbidity including hypertension, myocardial infarction, 
atrial fibrillation, congestive heart failure and stroke. The 
obstruction causes breathing to be interrupted for up to 
60s (with hypopnoea or complete apnoea), resulting in 
recurrent oxyhaemoglobin desaturations and arousals.1
There is a particularly high prevalence of OSA in 
patients with obesity and type 2 diabetes mellitus (T2DM) 
(23%–86%).2–4 Recently it has been shown that this rela-
tionship is bidirectional with insulin- treated diabetes asso-
ciated with a higher risk of OSA, particularly in women.5 If 
effective treatment is not administered, OSA is associated 
with significant long- term health risks including impaired 
quality of life,6 irritability and depression, decreased 
performance in work and potentially road traffic acci-
dents,7 hypertension, increased risk of microvascular 
complications8 and increased risk of stroke and cardiovas-
cular disease.9 The standard care option for OSA patients 
is continuous positive airway pressure (CPAP)10 which 
facilitates normal breathing patterns during sleep by 
splinting open the upper airway. Other treatment options 
include diet- induced weight loss,11 intensive lifestyle inter-
vention12 and metabolic (bariatric) surgery.13 Therefore, 
the beneficial effects of treatment may be derived from 
mechanical (CPAP) and/or metabolic interventions (diet 
and exercise); however, compliance with these current 
treatment pathways is poor. Weight loss is particularly 
difficult to achieve and the use of CPAP is usually associ-
ated with slight weight gain14 which may further exacer-
bate the associated metabolic complications.15 Thus, the 
optimal treatment strategy for a T2DM patient with OSA 
would involve concomitantly targeting both weight loss 
and glycaemic control (metabolic interventions) in addi-
tion to offering CPAP (mechanical intervention).16
This research study assesses the impact of pharmacolog-
ical treatment with liraglutide, a glucagon- like peptide-1 
receptor agonist (GLP- 1RA), a subcutaneously injected 
agent licenced for glucose lowering in T2DM at doses 
up to 1.8 mg.17 This therapy has also been licenced at 
higher dose (3 mg) for treatment of obesity18 19; however, 
it is important to note that this study commenced before 
approval of 3 mg dose of liraglutide. There have been 
limited studies examining the impact of liraglutide 
in patients with OSA.20 21 There is however very recent 
unpublished data, released by NovoNordisk, from the 
first completed phase 3a trial in the STEP programme, 
the STEP4 study (Semaglutide Treatment Effect in People 
with obesity), demonstrating the magnitude of weight loss 
observed with semaglutide, a once- weekly GLP- 1RA. Over 
a 68- week period, weight loss of up to ~18% of total body 
weight was observed. These results demonstrate greater 
weight loss than that previously observed with pharmaco-
therapy in individuals with obesity. It will be interesting 
to examine the impact of semaglutide, and the associated 
greater weight loss, in people with obesity complicated 
by OSA.
We aim to determine whether liraglutide, at the 1.8 mg 
dose approved for T2DM treatment, can provide a useful 
therapeutic adjunctive effect in patients with obesity, 
T2DM and OSA, either as a stand- alone treatment or as an 
adjunct to CPAP. The coexistence of obesity and insulin 
resistance in T2DM and OSA provides a strong rationale 
for the therapeutic administration of liraglutide to obese 
individuals with T2DM and OSA. We assess the effects of 
liraglutide on OSA symptoms and severity on glycaemic 
control in obese individuals with T2DM and OSA, either 
as a monotherapy (without CPAP) or in combination with 
CPAP. The data collected will help determine optimal 
treatment strategies for this challenging and increasingly 
common clinical disorder.
METHODS AND ANALYSIS
One hundred and thirty- two obese individuals (body 
mass index (BMI) ≥30 kg/m2) with a clinical diagnosis of 
T2DM and OSA will be recruited (with the aim of 128 
participants completing the study, n=32 per study arm) 
from across the Liverpool area from both primary and 
secondary care settings (diabetes and sleep medicine 
outpatient clinics and community care).
Primary objective
To determine whether 26 weeks of liraglutide treatment 
(up to 1.8 mg once per day) can provide a useful treat-
ment for patients with obesity, T2DM and OSA, either 
as a stand- alone treatment or as an adjunct to CPAP. 
The primary outcome measure of interest is change in 
apnoea–hypopnoea index (AHI) (the principal measure 
of OSA severity) from baseline.
Secondary objectives
The key secondary outcome measures are change in 
HbA1c (the principal measure of glycaemic control) 
from baseline and change in total body weight (kg). Addi-
tionally, the trial will provide useful measures of changes 
in daytime sleepiness (Epworth score) and quality of life 
and assess treatment compliance as well as the rate of 
adverse events.
Further exploratory outcome measures include 
changes in (i) physical activity (measured by a multi-
sensor array), (ii) fat volume and distribution (abdominal 
visceral adipose tissue, abdominal subcutaneous adipose 
tissue, neck fat, submental fat, tongue fat and liver fat) 
and skeletal muscle mass using MRI- based techniques, 
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(iii) cardiac function using transthoracic echocardiog-
raphy and (iv) arterial structure (carotid intima- media 
thickness (cIMT)) and function (flow- mediated dilata-
tion (FMD)) using duplex ultrasonography.
Trial design
This is an outpatient, single- centred, open- labelled, 
prospective, phase IV randomised controlled trial in a two- 
by- two factorial design. The trial is designed to provide 
evidence of benefit of liraglutide on the severity of OSA, 
body composition and cardiometabolic complications of 
OSA, when used alone or in combination with CPAP over 
a period of 26 weeks. Patient–public involvement was not 
incorporated into the design of this trial.
Methods: participants, interventions and outcomes
This protocol document reflects version 7. Various 
aspects of the protocol were updated based on early trial 
monitoring and evaluation by the research team and Trial 
Steering Committee (TSC).
Study setting
Patients will be recruited from T2DM and OSA clinics at 
University Hospital Aintree, Liverpool, UK commencing 
September 2015. Further patients will be sourced from 
approved patient identification centres consisting of 
community clinics across the Liverpool and Knowsley 
areas. Study sites are controlled and monitored by the 
Liverpool Cancer Trials Unit (LCTU), University of Liver-
pool. At study outset, we anticipated that five participants 
would be recruited per month based on clinic numbers. 
Initially, we projected study completion be 1 October 
2017; however early study monitoring revealed a slower 
recruitment rate, which was evaluated by the TSC, and 
recruitment was extended accordingly until March 2018. 
Study amendments were also submitted to maximise 
patient recruitment opportunities.
Eligibility criteria
Population
T2DM patients with OSA will be initially identified based 
on BMI >30 kg/m2, by screening with the STOP- BANG 
questionnaire, or based on clinical suspicion from the 
medical history in patients with T2DM. Patients managed 
by diet alone or any combination of metformin and sulfo-
nylureas can be included. Patients receiving Dipeptidyl 
peptidase (DPP- IV) inhibitors may be included if treat-
ment ceases before baseline tests. Patients with current 
CPAP usage or whose diabetes is treated at recruitment 
with pioglitazone, sodium- glucose co- transporter-2 
(SGLT2) inhibitors, GLP- 1RAs or insulin or any history of 
pancreatitis identified in medical history will be excluded. 
Patients with excessive sleepiness (Epworth Sleepiness 
Score (ESS) >14) will be discussed with a sleep consultant 
and excluded if they drive a heavy goods vehicle or have 
any other occupational risk if not treated.
Potentially eligible patients must perform a screening 
visit 2–21 days before randomisation to assess eligibility 
to participate as determined by the detailed inclusion/
exclusion criteria. This will include medical history and 
concomitant medications, physical examination, height, 
weight, waist and neck measurements, blood tests and 
an overnight home sleep study. Patients can only be 
randomised if the overnight sleep study confirms moder-
ate–severe OSA as assessed by polysomnographic criteria 
and HbA1c ≥47 mmol/mol. Detailed inclusion/exclusion 
criteria are summarised as follows.
Detailed inclusion criteria
1. Men or women, age 18–75 years.
2. A clinical diagnosis of T2DM.
3. HbA1c ≥47 mmol/mol.
4. BMI ≥30 kg/m2.
5. Currently treated with either diet or any combination 
of metformin and sulfonylureas (excluding patients 
treated with DPP- IV inhibitors*, pioglitazone, SGLT2 
inhibitors, GLP- 1RAs or insulin).
6. No current use of liraglutide treatment.
7. Patients with moderate–severe OSA as assessed by poly-
somnographic criteria, either by:
 ► AHI ≥15 events/hour with overnight domiciliary 
multichannel sleep study device (Nox T3).
 ► Overnight desaturation index (ODI; pulse oximetry): 
ODI≥10 (4% dip in oxygen saturation more than 10 
events/hour).
 ► Currently symptomatic for OSA, with daytime 
sleepiness.
*Patients who are currently treated with DPP- IV inhib-
itors can be included providing the treatment is discon-
tinued before baseline tests.
Detailed exclusion criteria
Medical history and concurrent diseases
1. Women of childbearing potential (WOCBP) who are 
not using adequate contraceptive methods or who 
are planning a pregnancy in the next 6 months.
2. Treatment with SGLT2 inhibitors, pioglitazone, sub-
cutaneous insulin injections or with any antiobesity 
medication (eg, orlistat). We wished to avoid other 
glucose- lowering drugs that would either promote 
weight loss (SGLT2 inhibitors) or weight gain (piogl-
itazone or insulin). DPP- IV inhibitors were contrain-
dicated as they cannot be used in patients who take 
GLP1- RA.
3. Patients in whom there may be occupational implica-
tions to a diagnosis of OSA, for example, professional 
drivers or machinery operators.
4. Type 1 diabetes mellitus.
5. Congestive heart failure class III–IV.
6. Renal impairment: estimated glomerular filtration 
rate < 30 mL/min/1.73 m2.
7. Previous history of acute pancreatitis.
8. Hyperthyroidism.
9. Hypothyroidism (participants with a normal circu-
lating thyroid stimulating hormone (TSH) and free 
thyroxin (T4) concentrations, and on a stable dose 
of thyroxine for at least 3 months may be included).
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10. Uncontrolled hypertension (blood pressure 
≥170/120 mm Hg).
11. Recent (<6 months) myocardial infarction.
12. Previous stroke (with residual neurological deficit).
13. Significant cardiac dysrhythmias (including pacemak-
er or implantable cardioverter defribrillator (ICD)).
14. Presence of any other medical condition that would, 
in the opinion of the investigator or their clinician, 
preclude safe participation in the study. This decision 
should be informed by liraglutide precautions for use 
statements which will be provided to all clinicians and 
the research team.
15. Alcohol consumption in excess of daily recommend-
ed limits (21 units/week women, 28 units/week 
men). Alcohol consumption was determined using 
simple recall.
16. History of seizures or unexplained syncope.
17. Severe sleepiness*.
* If a patient scores >14 on the Epworth Sleepiness 
Scale, the sleep apnoea specialist will be consulted to 
assess and that confirm inclusion/exclusion criteria are 
met, especially regarding driving, but will not be an auto-
matic exclusion.
Allergies and adverse drug reactions
Participants with a history of any serious hypersensitivity 
reaction to GLP- 1RA.
Sex and reproductive status
1. WOCBP who are unwilling or unable to use an accept-
able method to avoid pregnancy for the study duration 
plus 8 weeks.
2. Women who are pregnant or breastfeeding.
Prohibited treatments and/or therapies
1. Diabetes treated with pioglitazone, GLP- 1RA ana-
logues or insulin.
2. Use of other weight loss medication or any drug that 
might affect body weight or appetite (including antide-
pressants, antipsychotics and corticosteroids).
Other exclusion criteria
1. Prisoners or participants who are involuntarily 
incarcerated.
2. Participants who are compulsorily detained for treat-
ment of either a psychiatric or physical (eg, infectious) 
illness.
Additional exclusion criteria for MRI scanning
1. Any history of internal metal, pacemakers, ferromag-
netic metallic implants, intraocular foreign bodies or 
cerebral aneurysm clips.
2. Weight >250 kg (due to limitations of MRI scanner).
Outcome measures
Over the course of three visits (figure 1), the following 
outcomes will be assessed in all patients at baseline and 
following the 26- week intervention period. For those 
patients treated with CPAP, we will perform an additional 
overnight sleep study at the end of the study period, while 
receiving CPAP and after 4–7 days of CPAP withdrawal.
Primary outcomes
The primary outcome variable is AHI22 derived via 
an overnight multichannel sleep study (NOX T3 PSG 
Recorder, Nox Medical, Reykjavik, Iceland). Although a 
number of studies using CPAP have used the ESS as the 
primary outcome measure, for the present study analysis 
of the ESS may lead to misleading conclusions as excessive 
daytime sleepiness is very common in obese and T2DM 
participants and is not restricted to those with OSA, 
particularly in patients with poor glycaemic control.23
Secondary outcomes
Anthropometric measurements
Weight, height and waist and hip circumference will be 
measured by a single research technician. Participants 
will then be rested for 5 min before blood pressure will be 
determined from an average of three measures.
Questionnaires
A series of self- assessed health and sleep questionnaires 
will be administered including: (i) STOP- BANG ques-
tionnaire (sleep apnoea questionnaire), (ii) BERLIN 
questionnaire (risk of sleep- disordered breathing), (iii) 
Epworth Sleepiness Scale (index of excessive daytime 
somnolence), (iv) SF-36 (self- administered questionnaire 
to determine quality of life) and (v) SAQLI (sleep apnoea 
quality of life index), a sleep apnoea- specific quality of 
life questionnaire.
Oxford sleep resistance test (OSLER)
The OSLER test, a modified measure of the ‘mainte-
nance of wakefulness’ test that gives a validated objective 
measure of sleepiness, will be performed.23 The test uses 
a small LED that lights up every 3 s, which the patient is 
required to cancel by tapping a sensor while sitting on a 
standard chair in a quiet dark room. The test will be termi-
nated if the patient misses a number of lights in succes-
sion, at which point the patient is considered to have 
fallen asleep. Time to sleep onset and/or the number of 
misses over a 40 min period will be recorded. The test will 
be carried out once during the day and will be repeated 
post- intervention.
Biochemical analysis
All patients will have a routine 15 mL blood sample taken 
for glucose, insulin, lipid profile and liver function tests. 
Insulin sensitivity will be measured by homeostatic model 
assessment of insulin resistance (HOMA- IR).24
CPAP and liraglutide compliance
We shall examine CPAP usage within the first 3 months 
of the study, and CPAP usage >4 hours per night will be 
taken as adherent with total hours and average usage also 
reported. Similarly, for liraglutide we shall look at patient 
records and prescriptions returned from pharmacy where 
this information is available/recorded.
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Exploratory analyses and substudies
Physical activity monitoring
Physical activity will be tracked throughout using a Sense-
Wear mini armband (BodyMedia, Pittsburgh, Penn-
sylvania) for a 4- day period. Patients will be instructed 
to wear at all possible times. Data collected from the 
armband include: daily average step count, total energy 
expenditure, active energy expenditure and time spent in 
domains of physical activity including sleep, lying, seden-
tary (<1.5 metabolic equivalents (METS)), light (1.5–3 
METS), moderate (3–6 METS), vigorous (6–9 METS) 
and very vigorous (>9 METS) and are analysed using 
SenseWear Professional software (V.8.0).
Food diaries
Patients will be asked to complete a food diary detailing 
exactly what they eat and drink over the same 4- day period. 
Total energy consumption, carbohydrate, protein and fat 
content will be determined from dietary records using 
Nutritics (Nutrition Analysis Software for Professionals).
Cardiorespiratory fitness
A V̇O2peak cardiopulmonary exercise test (CPET) will be 
performed on a treadmill (Model 77OCE, RAM Medisoft 
Group, Manchester, UK) in a temperature- controlled 
room. The CPET provided breath- by- breath monitoring 
and analysis of expiratory gases and ventilation as well 
as continuous ECG monitoring (Love Medical Cardio-
pulmonary Diagnostics, Manchester, UK). The modified 
Bruce protocol will be employed, after an initial 2 min 
warm- up at 2.2 km/h on a flat gradient, stepwise incre-
ments in speed and gradient were employed each minute. 
V̇O2peak was determined by any of the following: respi-
ratory exchange ratio >1.15, heart rate >90% predicted 
maximum, plateau in V̇O2 or exhaustion.
Body composition, neck anatomy and liver fat
MRI will be carried out at the Liverpool Magnetic Reso-
nance Imaging Centre (LiMRIC), University of Liver-
pool using a Siemens Symphony 1.5T MR scanner. For 
body composition, transverse whole- body MRI data will 
be acquired using a T1- weighted turbo spin- echo (TSE) 
sequence with 1 cm slice thickness and gap.
From these scans, subcutaneous and visceral fat content 
will be determined using serial sections of the trunk and 
skeletal muscle mass from serial sections of the thigh. 
Liver proton magnetic resonance spectroscopy (1H 
MRS) will be performed at three standardised sites using 
the integral body coil with TR 1500 ms TE 135 ms, free 
Figure 1 Schematic of protocol. AHI, apnoea–hypopnoea index; BMI, body mass index; CPAP, continuous positive airway 
pressure; ECHO, echocardiogram; ESS, Epworth Sleepiness Score; FMD, flow- mediated dilatation; HbA1c, glycated 
haemoglobin; NOX, sleep testing device; ODI, overnight desaturation index; OSA, obstructive sleep apnoea; QoL, quality of life; 
SAT, subcutaneous adipose tissue; SU, sulphonylureas; T2DM, type 2 diabetes mellitus; VAT, visceral adipose tissue.
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breathing. 1H MRS data will be analysed to determine 
intrahepatic triglyceride concentration as marker of non- 
alcoholic fatty liver disease. To assess the neck anatomy, 
T1- weighted TSE axial contiguous 4 mm slices will be 
acquired from the hard palate to the vocal chords, using 
a cervical spine coil with participants lying supine and 
breathing quietly through their nose.25 Within the region 
of interest, volumetric measurements of submental fat, 
neck fat, tongue, soft palate, lateral pharyngeal walls and 
airway will be obtained (figure 2).
Endothelial function
A 10 MHz multifrequency linear array probe attached to 
a high- resolution ultrasound machine (Siemens Medical 
Solutions, Malvern, Pennsylvania) will be used to image 
the brachial artery in the distal third of the upper right 
arm. Once an optimal image is acquired, the probe is 
held stable and the ultrasound parameters set to optimise 
longitudinal, B- mode images of the lumen–arterial wall 
interface. Continuous Doppler velocity assessment will 
also be used. Nitric oxide- mediated endothelial func-
tion will be assessed by measuring FMD in response to a 
5 min ischaemic stimulus, induced by forearm cuff infla-
tion.26 Baseline images will be recorded using specialised 
recording software (Camtasia; TechSmith, Okemos, Mich-
igan). A rapid inflation and deflation pneumatic device 
(D.E. Hokanson, Bellevue, Washington) will be used 
with an inflation cuff placed immediately distal to the 
olecranon process of the imaged arm to provide a stim-
ulus for forearm ischaemia. A baseline recording lasting 
1 min will be acquired before the forearm cuff is inflated 
(È220 mm Hg) for 5 min. Artery diameter and blood flow 
velocity recordings resumed 30 s before cuff deflation 
and continued for 3 min thereafter.26 Peak brachial artery 
diameter and blood flow velocity, and the time taken to 
reach these peaks after cuff release, will be recorded.
Vascular structure
An image of the carotid artery will be recorded using the 
same technology and measurement of cIMT, or artery 
wall thickness, will be calculated using custom- designed 
software.27 In brief, the anterolateral, posterolateral and 
mediolateral planes are to be acquired. Patients will be 
instructed to lay supine with a slight hyperextension of 
the neck and a 45° lateral flexion away from the side being 
scanned (right). An R-wave triggered optimal recording 
of the far wall, 1 cm proximal to the carotid bulb, will be 
stored as a digital DICOM file on the PC for analysis of 
cIMT and common carotid arterial diameter.
Cardiac structure and function
Indices of cardiac function and subclinical indices of 
myocardial systolic and diastolic function (strain and 
strain rate) will be determined using tissue Doppler echo-
cardiography.28 All echocardiograms will be performed 
using a GE Vivid 7 or E9 machine with a 2.5 MHz phased 
array transducer and the patient in the left lateral posi-
tion on a reclining couch. A combination of 2D, M- mode, 
pulsed wave and continuous wave Doppler and tissue 
Doppler is to be used. Conventional echocardiographic 
views will be obtained (parasternal long axis, parasternal 
short axis, apical four chamber, apical long axis, apical 
two chamber and subcostal).
Left ventricular (LV) diameter and wall thicknesses 
will be measured in the parasternal long axis view using 
two- dimensional or M- mode measurements. LV mass will 
be calculated using the Devereux formula and indexed 
to body surface area. Modified Simpson’s biplane 
method will be used to determine LV ejection fraction. 
Mitral inflow velocities and deceleration times are to be 
measured using pulsed wave Doppler in the apical four- 
chamber view. Isovolumetric relaxation time will also 
be calculated using continuous wave Doppler, with the 
cursor midway between LV outflow and mitral inflow. For 
tissue Doppler imaging, colour tissue Doppler loops will 
be recorded using a frame rate >100 frames/s. Myocardial 
longitudinal function will be assessed from three consec-
utive cycles of tissue Doppler imaging in the apical four- 
chamber, apical two- chamber and apical long- axis views.
Echocardiographic data has to be analysed using 
Echopac V.9.01 (GE, Horten, Norway). Peak systolic and 
early and late diastolic myocardial tissue velocities will 
Figure 2 MRI (T1- weighted, spin echo, 4 mm slice 
thickness) showing the mid- sagittal slice of head and neck. 
Region of interest includes all tissues inferior to hard palate 
and superior to vocal cords. The following structures to 
be included in analysis have been highlighted: submental 
fat, defined as all fat anterior to hyoid and inferior to 
mandible; tongue (genioglossus); soft palate; airway; lateral 
parapharyngeal walls; internal neck fat; subcutaneous neck 
fat.
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be obtained from the basal segment of all six LV walls. 
Myocardial deformation curves will be obtained from 
the basal segment of all six LV walls. Wall motion will 
be manually tracked throughout the cardiac cycle to 
maintain continuity of the sampling area. Data will be 
excluded if a smooth curve was unobtainable, or if the 
angle between the ventricular wall and the scan line was 
>200. From these curves, peak systolic strain, systolic and 
early and late diastolic strain rates will be obtained. Using 
data from each of the three cardiac cycles, the values from 
each wall can be averaged to give a mean value.
Follow- up Investigation Repeat procedures identical 
to the baseline visits will be performed at the end of the 
26- week intervention period. Importantly, the time of day 
of these assessments will remain consistent to control for 
circadian variation.
Interventions
Patients will be randomised in equal allocation to one of 
the four arms:
 ► Arm A: Control arm, comprising conventional care 
for existing patients with T2DM with no intervention 
for OSA.
 ► Arm B: Conventional care, plus liraglutide (up to 
1.8 mg once per day).
 ► Arm C: Conventional care, plus CPAP.
 ► Arm D: Conventional care, plus liraglutide (up to 
1.8 mg once per day) and CPAP.
Randomisation
Sequence generation
Patients will be allocated equally to each of the four treat-
ment arms using computer- generated random, permuted 
blocks of unequal sizes. This will be created by the trial 
statistician in accordance with the LCTU’s standard oper-
ating procedure. The allocation sequence will be held 
centrally at the LCTU with access confined to the trial 
statistician, the LCTU trial coordinator and the data 
managers assigned to the study.
Control (no intervention)
This group will not use placebo medication. Patients will 
be asked to continue with their usual antidiabetic medi-
cations and if titration of any glucose- lowering therapy is 
necessary, due to worsening glycaemic control, this will 
be recorded. This diabetes therapy titration may include 
initiation of subcutaneous insulin therapy if glycaemic 
control significantly deteriorates. Patients will not be 
given CPAP for this period for their OSA.
Liraglutide
Liraglutide is administered as a once per day subcuta-
neous injection in the abdomen, thigh or upper arm. 
It will be commenced at a starting dose of 0.6 mg once 
per day, increasing after 1 week to 1.2 mg once per day 
and after a further week to 1.8 mg once per day. Those 
patients who cannot tolerate the increased dose after the 
first week will be asked to remain at 0.6 mg/day and will 
be rechallenged with 1.2 mg dose accordingly. Should 
drug intolerance persist, patients will be asked to remain 
on the lowest, tolerated dose. This will be managed by the 
research team on an individual basis. The trial- specific 
prescription will allow the prescriber to specify individual 
doses and quantities for those patients who do not tolerate 
the intended dose. Due to the dose- escalation nature of 
the trial design, dose modifications are not appropriate.
Continuous positive airway pressure
The CPAP device that will be used will be the ResMed 
AirSense 10 Elite in a fixed pressure delivery mode, with 
the therapeutic pressure defined in accordance with stan-
dard clinical protocols.29
Preparation, dosage and administration of study treatment
Existing clinical staff within the relevant diabetes and 
sleep clinics at University Hospital Aintree will initiate 
the appropriate treatment pathway in patients enrolled 
onto the study according to their randomisation. It is 
important to note that individuals who enrol onto the 
study will be fast- tracked through the referral pathways 
and will commence their allocated treatment immedi-
ately following baseline assessment.
Additional visits
Additional visit for patients randomised to arms B, C and 
D to collect the CPAP device, liraglutide prescription and 
instructions for use. This is optional for arm A patients 
who should be given the choice of a visit or telephone 
consultation.
Female patients randomised to liraglutide will require 
an additional pregnancy test (within 0–72 hours before 
the first dose of study drug).
Assessment of compliance with study treatment
All patients randomised to arms B or D will be instructed 
to return used (empty or part full) liraglutide pens at each 
prescribing visit. These are assessed by pharmacy staff 
and volumes recorded and compliance can be calculated 
accordingly as percentage used per protocol and per indi-
vidual prescription (if maximum dose is not tolerated).
The CPAP device will be interrogated to determine 
the duration of usage (minutes per night) with the usage 
recorded on the case report form (CRF). The initial 3 
months of CPAP data will be used for study analysis as per 
remote monitoring with Airview (Resmed) or by down-
loading the CPAP machine directly. Compliance calcula-
tions will be described in greater detail in the statistical 
analysis plan but patients returning their machine will 
still remain in their allocated study arm. Patients will 
also be issued with treatment diaries to facilitate discus-
sion at each study visit and the data will also be recorded. 
Patients will be routinely counselled on the importance of 
using their study intervention as prescribed.
Monitoring/dispensing visits
Follow- up visits or telephone calls for patients randomised 
to arms B, C and D will take place at weeks 2, 4 and 6 of 
treatment intervention to review drug- related side effects 
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and assessment of any CPAP- related issues and compli-
ance with regimen. Patients in arm A will be reviewed by 
telephone conversation.
After 6 weeks, specialist T2DM and OSA nurses will 
provide fortnightly telephone support to all patients and 
where necessary face- to- face reviews to monitor patient 
compliance to treatment pathways and manage their drug 
escalation and deal with any problems identified with the 
CPAP device (liraglutide and liraglutide +CPAP arms).
For patients randomised to arms A and B, these are 
repeat procedures identical to visits 2, 3 and 4
For patients randomised to arms C and D who have 
been issued with a CPAP device, an additional sleep study 
will be performed at visit 10 following a period of 4–7 days 
without CPAP.
Study withdrawal
If a patient wishes to withdraw from trial treatment, the 
importance of remaining on trial follow- up, or failing 
this, of allowing routine follow- up data to be used for 
trial purposes, will be explained. Generally, follow- up 
will continue unless the patient explicitly also withdraws 
consent for follow- up.
Patients who withdraw from the trial for other reasons 
have previously consented to follow- up in the trial. Data 
up to this time can be included in the trial if anonymised. 
They may need to reaffirm that they consent to follow- up 
through usual NHS mechanisms. If the patient explic-
itly states their wish not to contribute further data to the 
study, an End of Study CRF should be completed docu-
menting the reason for withdrawal. It must be noted that 
any safety data collected up to the point of withdrawal 
cannot be removed from the trial analysis.
Pharmacovigilance
All adverse events and assignment of the severity/grading 
(mild, moderate, severe, life- threatening, death) made by 
the investigator responsible for the care of the participant 
will be reported. The assignment of causality will be made 
by the chief investigator. All non- serious adverse events 
(SAEs), whether expected or not, will be recorded and 
updated at each study visit. All new SAEs will be reported 
from the point of consent until 70 days after discontinua-
tion of the investigational medical product; this includes 
those thought to be associated with protocol- specified 
procedures. Investigators will report SAEs, serious adverse 
reactions (SARs) and sudden unexpected SARs (SUSARs) 
to LCTU within 24 hours of the local site becoming aware 
of the event. LCTU will notify the Medicines and Health-
care products Regulatory Agency (MHRA) and main 
Research Ethic Committee (REC) of all SUSARs occur-
ring during the study: fatal and life- threatening SUSARs 
within 7 days of notification and non- life- threatening 
SUSARs within 15 days. All adverse events will be followed 
until satisfactory resolution or until the investigator 
responsible for the care of the participant deems the 
event to be chronic or the patient to be stable.
Statistical analysis plan
Sample size calculation
We assume a clinically minimum relevant difference in 
AHI between control and intervention groups of ~10 units, 
approximating the difference between the midpoints of 
mild and moderate AHI scores. This assumption is reason-
able based on a weight loss of ~5 kg being associated with a 
reduction in AHI of 14 units in patients with similar base-
line characteristics to those proposed in the current study.30
Treating the two- by- two factorial design as two unre-
lated comparisons, using the method for the unpaired 
t- test and based on a SD of 15 units,31 90% power and 
a 1% significance level, we require a total sample size of 
128 patients (64 in the marginal total for each group or 
32 in each arm). Considering a small dropout rate, this 
will entail screening approximately 132 patients. Given 
the non- invasive nature of the interventions and the short 
follow- up planned, patient retention is not envisaged to 
be an issue. Furthermore, early study withdrawals formed 
part of the evaluation by the joint data monitoring 
committee (DMC)/TSC oversight committee so that this 
assumption could be evaluated during the course of the 
study.
This sample size does not consider the possibility of an 
interaction effect, but without prior knowledge of any 
such interaction we believe that this assumption is reason-
able. Furthermore, we recognise that the power to detect 
an effect on HbA1c is low.
Statistical methods
Categorical variables will be summarised as frequencies 
and percentages. Continuous variables will be summarised 
as mean (95% SD). The analysis of the factorial design 
will use a general linear model with main effect terms for 
treatment together with baseline value of the response 
variable (for each of the response variables). Full details of 
the planned analyses will be given in a separate statistical 
analysis plan, to be completed and signed off before data 
lock. Data access is granted to assigned trial statisticians.
Subgroup analyses
A test for interaction will be performed. No others are 
specified at the time of writing.
Significance levels
For analysis of the primary outcome, statistical signifi-
cance will be declared if a two- sided p value of <0.05 is 
obtained in favour of liraglutide or CPAP. For the primary 
end point, the mean difference from baseline (adjusted 
for baseline) will be presented with a corresponding 95% 
two- sided CI. Secondary end points will also be presented 
with 95% CIs and 5% two- sided significance levels.
Analysis populations
The main analysis for primary and secondary end points 
will use the full analysis set, consisting of all randomised 
patients, with participants analysed according to the 
group to which they were originally allocated and with 
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outcomes included irrespective of protocol adherence, to 
follow the intention- to- treat principle.
The per- protocol population will consist of those patients 
in the full- analysis set without any major deviations in 
treatment or assessment that could affect the outcome. 
This population will be used in a sensitivity analysis for 
the primary end point. The safety population, consisting 
of all patients who actually receive a trial intervention, 
according to the treatment received, will be used for anal-
ysis of toxicity and adverse events.
Missing data
Missing data will be handled by multiple imputation 
(MI), performing separate MIs by treatment arm, using 
the method of chained equations as implemented in 
Stata V.12 or higher. Imputation is planned only for cases 
of missing follow- up outcome data which is anticipated to 
be small, and therefore the scope for any bias due to the 
MI routine is limited. MI using chained equations will be 
applied to each treatment arm individually. Imputation 
methods will include baseline outcome data and other 
key prognostic information (eg, sex and age).
Safety analysis
Information related to adverse events (eg, hypogly-
caemia) will be tabulated and summarised descriptively.
Trial oversight
Management structure
The trial will be overseen by a TSC and operated on a 
day- to day basis by a trial management group (TMG). The 
trial coordinator (TC) will produce monthly recruitment 
reports, to allow the TSC and TMG to regularly review 
the trial across sites. The TSC will comprise of experi-
enced medical experts and trialists. Meetings will be held 
at regular intervals dependent on need, but no less than 
once a year. The responsibilities will include as follows:
a. Report to the TSC.
b. Maintain the Trial Master File.
c. Confirm all approvals are in place before release of 
the trial treatment and the start of the trial at a site.
d. Provide training about the trial.
e. Provide study materials.
f. Data management centre.
g. Give collaborators regular information about the 
progress of the study.
h. Respond to any questions (eg, from collaborators) 
about the trial.
i. Ensure data security and quality and observe data 
protection laws.
j. Safety reporting.
k. Ensure trial is conducted in accordance with the 
International Conference on Harmonisation Good 
Clinical Practice (ICH GCP).
l. Statistical analysis.
m. Publication of trial results.
The role of the TSC is to provide overall supervision 
of the trial. In particular, the TSC will concentrate on 
the progress of the trial, adherence to the protocol, 
patient safety and consideration of new information. 
The TSC must be in agreement with the final protocol 
and, throughout the trial, will take responsibility for:
a. Major decisions such as need to change the protocol 
for any reason.
b. Monitoring and supervising the progress of the trial.
c. Reviewing relevant information from other sources.
d. Considering recommendations from the DMC.
e. Informing and advising the TMG on all aspects of the 
trial.
Patient and public involvement
No patient or public involvement.
ETHICS AND DISSEMINATION
This study is being conducted in accordance with GCP, 
as defined by the ICH and in compliance with the Euro-
pean Union Directive 2001/20/EC transposed into UK 
law as statutory instrument 2004 No. 1031: Medicines 
for Human Use (Clinical Trials) Regulations 2004 and 
all subsequent amendments and the United States Code 
of Federal Regulations, Title 21, Part 50 (21CFR50). 
The trial protocol has received the favourable opinion 
of the NRES North West—Liverpool Central Research 
Ethics Committee (14/NW/1019; protocol number 
UoL000977). An appropriate patient information 
sheet and consent forms (online supplementary files) 
describing in detail the trial interventions/products, 
trial procedures and risks were approved by the ethical 
committee. The investigator will then explain the 
study to the patient and answer any questions posed. A 
contact point where further information about the trial 
may be obtained will be provided. After being given 
adequate time to consider the information, the patient 
will be asked to sign the informed consent document 
by a member of the study team. A copy of the informed 
consent document will be given to the patient for their 
records and a copy placed in the medical records, with 
the original retained in the investigator site file. The 
patient may withdraw from the trial at any time by 
revoking their informed consent. The rights and welfare 
of the patients will be protected by emphasising to them 
that the quality of medical care will not be adversely 
affected if they decline participation.
The results will be analysed together and published as 
soon as possible. The Uniform Requirements for Manu-
scripts Submitted to Biomedical Journals (http://www. 
icmje. org/) will be respected. The ISRCTN allocated to 
this trial would be attached to any publications resulting 
from this trial.
Dissemination plan (publications, data deposition and 
curation)
It is our intention to present our research findings to 
all our research participants in a written lay summary 
and hold an open feedback session where the results 
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will be presented in a lay- friendly manner. We plan to 
present the scientific findings as oral communications 
and abstracts at regional, national and international 
scientific meetings related to obesity, T2DM, respira-
tory and sleep medicine. We also intend to publish our 
findings in peer- reviewed journals in the subspecialties 
described earlier.
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